Comparative Pharmacology
Head-to-head clinical analysis: CHIRHOSTIM versus GENOTROPIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHIRHOSTIM versus GENOTROPIN.
CHIRHOSTIM vs GENOTROPIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic tripeptide (l-prolyl-l-lysyl-l-phenylalanyl) that stimulates phagocytosis via activation of mononuclear phagocytes and polymorphonuclear leukocytes through binding to formyl peptide receptors (FPRs), enhancing chemotaxis, superoxide production, and bactericidal activity. Also enhances natural killer (NK) cell activity and modulates cytokine release (e.g., IL-1, IL-6, TNF-α).
Recombinant human growth hormone (somatropin) binds to growth hormone receptors, activating JAK2/STAT5 signaling pathway, stimulating IGF-1 production and promoting linear growth, protein synthesis, and lipolysis.
Subcutaneous injection: 0.5 mg/kg once daily. Maximum dose: 40 mg/day.
0.2 mg (0.6 IU) subcutaneously once daily; titrate based on clinical response and IGF-1 levels. Maximum dose: 0.8 mg (2.4 IU) daily.
None Documented
None Documented
Terminal elimination half-life is 14-16 hours; clinically, steady-state is achieved in approximately 3-4 days.
Subcutaneous: 3.9 hours (range 2.3–6.1 hours). Clinical context: supports daily dosing; residual GH activity may extend due to reversible binding to GHBP.
Primarily renal (70-85% as unchanged drug); biliary/fecal (10-20%) with enterohepatic recirculation.
Renal (glomerular filtration and tubular reabsorption); approximately 70% of the administered dose is recovered in urine, primarily as intact hormone.
Category C
Category C
Growth Hormone
Growth Hormone